SAB Biotherapeutics Statistics Share Statistics SAB Biotherapeutics has 10.41M
shares outstanding. The number of shares has increased by 0.68%
in one year.
Shares Outstanding 10.41M Shares Change (YoY) 0.68% Shares Change (QoQ) 0.68% Owned by Institutions (%) 23.78% Shares Floating 8.39M Failed to Deliver (FTD) Shares 981 FTD / Avg. Volume 0.07%
Short Selling Information The latest short interest is 745.63K, so 8.02% of the outstanding
shares have been sold short.
Short Interest 745.63K Short % of Shares Out 8.02% Short % of Float 10.15% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.03 and the forward
PE ratio is -1.77.
SAB Biotherapeutics's PEG ratio is
0.02.
PE Ratio -1.03 Forward PE -1.77 PS Ratio 26.55 Forward PS 56.7 PB Ratio 1.35 P/FCF Ratio -1.01 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.98,
with a Debt / Equity ratio of 0.18.
Current Ratio 2.98 Quick Ratio 2.98 Debt / Equity 0.18 Debt / EBITDA -0.16 Debt / FCF -0.13 Interest Coverage -134.77
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $20.98K Profits Per Employee $-541.35K Employee Count 63 Asset Turnover 0.03 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -18.05% in the
last 52 weeks. The beta is 0.54, so SAB Biotherapeutics's
price volatility has been higher than the market average.
Beta 0.54 52-Week Price Change -18.05% 50-Day Moving Average 2.17 200-Day Moving Average 2.35 Relative Strength Index (RSI) 49.93 Average Volume (20 Days) 1,432,082
Income Statement In the last 12 months, SAB Biotherapeutics had revenue of 1.32M
and earned -34.1M
in profits. Earnings per share was -3.68.
Revenue 1.32M Gross Profit -3.47M Operating Income -42.91M Net Income -34.1M EBITDA -28.99M EBIT -33.79M Earnings Per Share (EPS) -3.68
Full Income Statement Balance Sheet The company has 8.9M in cash and 4.67M in
debt, giving a net cash position of 4.23M.
Cash & Cash Equivalents 8.9M Total Debt 4.67M Net Cash 4.23M Retained Earnings -124.17M Total Assets 30.13M Working Capital -1.37M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -34.29M
and capital expenditures -337.26K, giving a free cash flow of -34.63M.
Operating Cash Flow -34.29M Capital Expenditures -337.26K Free Cash Flow -34.63M FCF Per Share -3.74
Full Cash Flow Statement Margins Gross margin is -262.48%, with operating and profit margins of -3245.92% and -2579.8%.
Gross Margin -262.48% Operating Margin -3245.92% Pretax Margin -2579.8% Profit Margin -2579.8% EBITDA Margin -2193.19% EBIT Margin -3245.92% FCF Margin -2619.46%
Dividends & Yields SABS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SABS is $11.5,
which is 427.5% higher than the current price. The consensus rating is "Buy".
Price Target $11.5 Price Target Difference 427.5% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 5, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Jan 5, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -9.85 Piotroski F-Score 1
